EFG Capital International’s Charles River Laboratories CRL Stock Holding History

EFG Capital International’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$230K	Buy	+1,092	New	+$217K	0.05%	137

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

EFG Capital International's CRL Position: Q2 2023 in Review

EFG Capital International opened a new position in Charles River Laboratories (CRL) in Q2 2023: 1,092 shares worth $230K. The stake represents 0.05% of the portfolio and ranks #137 among its holdings.

611 funds tracked by Wall St. Rank hold CRL as of Q2 2023.

EFG Capital International held 1,092 shares of Charles River Laboratories worth $230K as of Q2 2023.
Charles River Laboratories was a new EFG Capital International position in Q2 2023.
Charles River Laboratories made up 0.05% of EFG Capital International's portfolio in Q2 2023, its #137 holding.
611 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2023.

Based on EFG Capital International's 13F filing for Q2 2023, filed 2 Aug 2023.